De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?

Abstract excerpt

De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5-10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. This review describes the current therapeutic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Lipids, and Metabolism
• Share to Prostate Cancer Treatment and Research
• Share to Radiopharmaceutical Chemistry and Applications